Prime Medicine, Inc.
Prime Medicine, Inc. is a U.S.-based biotechnology company developing Prime Editing, a gene-editing platform designed to make precise DNA changes for genetic diseases and other disorders. The company’s pipeline includes wholly owned in vivo programs, an ex vivo cell-therapy collaboration, and early discovery efforts, with operations centered in Cambridge, Massachusetts.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCore gene-editing technology used to create precise DNA edits across multiple therapeutic programs.
Liver-directed genetic medicine programs targeting Wilson Disease, AATD, and related indications.
Program for chronic granulomatous disease intended to validate Prime Editing in humans.
Partnered cell-engineering work with BMS applying Prime Editing to T-cell therapies.
Early-stage research, LNP delivery, manufacturing, and IND-enabling development work.
Customers
Prime Medicine does not sell commercial products; its current customers are collaboration partners and, in the future, regulators and healthcare providers if programs reach approval. Revenue to date has come from research collaboration and license agreements, while the underlying therapeutic end markets are patients with serious genetic diseases and immune/oncology disorders.
Pharmaceutical and biotech partners that pay for access to Prime Editing capabilities, shared development, or licensed programs.
Patients with defined genetic disorders such as Wilson Disease, AATD, and CGD who would use approved therapies if developed.
Partners and future treatment centers involved in ex vivo T-cell engineering and related cell therapy applications.
Academic, foundation, and disease-advocacy collaborators that support discovery, data generation, and program advancement.
Strategy
The company’s strategy is to advance Prime Editing from platform validation into clinical development, starting with liver-directed programs and PM359. It also uses partnerships, such as BMS, to expand the platform into ex vivo applications while preserving internal focus on its highest-priority in vivo pipeline.
Wilson Disease and AATD are core franchise opportunities and near-term clinical catalysts.
Clinical proof-of-concept supports platform credibility and future partnering.
Partnerships can add capabilities and funding without overextending internal resources.
Clinical-stage execution requires manufacturing, quality, and regulatory readiness.
Geography
Prime Medicine is headquartered in Cambridge, Massachusetts and operates as a U.S.-based development-stage biotech company. Its business is primarily organized around U.S. research, clinical, and regulatory activities, while collaborations and future development work may extend into Europe and other markets through partners and trial sites.
Risks
Prime Medicine faces the typical risks of a pre-commercial biotech: clinical failure, regulatory delays, and dependence on external capital and partners. Its platform also depends on complex manufacturing, intellectual property protection, and third-party supply chains, including some China-linked inputs that could be disrupted by geopolitical or policy changes.
- Clinical development failureImpact: CriticalLikelihood: Medium
Prime Editing programs are still in preclinical or early clinical stages and may not translate into approved therapies.
Exposure - Regulatory delay or non-approvalImpact: HighLikelihood: Medium
Gene-editing therapies require extensive FDA/EMA review and may need additional data or longer follow-up.
Exposure - Financing and going-concern pressureImpact: HighLikelihood: Medium
The company has no product sales and depends on external funding to sustain development.
Exposure: Operating runway and program continuity
- Partner concentration and collaboration executionImpact: HighLikelihood: Medium
A meaningful portion of value creation depends on successful third-party collaborations and license arrangements.
Exposure: BMS collaboration and future strategic deals
- Supply chain and geopolitical exposureImpact: MediumLikelihood: Low
Preclinical and clinical development may rely on China-based suppliers or service providers that could be restricted.
Exposure
Accounting
Judgemental itemsRevenue timing depends on identifying performance obligations and estimating progress over time.
Impact: Can shift revenue between periods without changing cash receipts
Black-Scholes assumptions such as volatility and expected term drive expense recognition.
Impact: Can materially affect operating expenses and equity compensation cost
Clinical and preclinical costs are often estimated before invoices are received.
Impact: Can change reported R&D expense and liabilities
Future milestone, royalty, and patent maintenance payments depend on uncertain events.
Impact: Creates off-balance-sheet style economic obligations and expense uncertainty
Similar listed companies
Publicly listed companies with a comparable business focus.
Beam Therapeutics Inc.
BEAM · Biological Products, (No Diagnostic Substances)
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026